Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Shortage Threat From Second COVID-19 Wave

Problems Are Expected But API Supplies May Not Be At Great Risk

Executive Summary

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

You may also be interested in...



India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise

A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.

UK Prepares For New International Regulatory Reliance Framework

From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.

Industry Warns Of New Post-Brexit ‘Cliff Edge’ For Medicines Supply To Northern Ireland

The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel